What is Kiromic?
Kiromic BioPharma, Inc. is a clinical-stage biotherapeutics firm leveraging its proprietary DIAMOND AI platform for the discovery, validation, and development of cell and gene therapies. The company's primary therapeutic focus is on immuno-oncology, with a key development initiative centered on ALEXIS, an allogeneic CAR-T cell therapy platform designed to target solid cancers by utilizing gamma delta T-cells. The DIAMOND AI platform integrates data science with target identification, aiming to drastically reduce the time and cost associated with cellular therapeutic development. Kiromic operates from its offices in Houston, Texas.
How much funding has Kiromic raised?
Kiromic has raised a total of $15M across 1 funding round:
Stock Offering
$15M
Stock Issuance/Offering (2020): $15M, investors not publicly disclosed
What's next for Kiromic?
The substantial enterprise-level funding and recent strategic investment indicate a strong market validation for Kiromic's AI-driven approach to cell and gene therapy development. This capital infusion is expected to accelerate the clinical progression of its ALEXIS platform and further enhance the capabilities of its DIAMOND AI technology. The company's focus on immuno-oncology and solid tumor targets suggests a strategic move into a high-demand area of biopharmaceutical research, positioning Kiromic for significant growth and potential market disruption.
See full Kiromic company page
